<DOC>
	<DOCNO>NCT00316199</DOCNO>
	<brief_summary>The purpose study determine response rate gemcitabine-paclitaxel combination administer 3-weekly schedule Chinese patient unresectable , locally recurrent breast cancer metastatic breast cancer .</brief_summary>
	<brief_title>Efficacy Study Gemcitabine-Paclitaxel Treat Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Female patient Chinese origin histologically cytologically proven diagnosis breast cancer . Unresectable , locally recurrent breast cancer stage IV disease . Have least one measurable lesion define Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion . Performance Status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Scale Treatment anthracyclinebased chemotherapy regimen adjuvant/neoadjuvant set subsequent disease relapse . Prior chemotherapy unresectable , locally advanced breast cancer metastatic disease . Concurrent administration tumor therapy , include cytotoxic chemotherapy , hormonal therapy , immunotherapy . Known suspected brain metastasis second primary malignancy clinically detectable time consideration study enrollment . Active infection serious condition . Pregnant breastfeeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>